|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xia C, Dong X, Li H, Cao M, Sun D, He S,
Yang F, Yan X, Zhang S, Li N and Chen W: Cancer statistics in China
and United States, 2022: Profiles, trends, and determinants. Chin
Med J (Engl). 135:584–590. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xu L, Zhang Y, Wang X, Shi M, Wang J, Tang
Y, Fu Y, Zhou Z and Chen M: Transarterial infusion chemotherapy
(TAI) combined with Sintilimab in locally advanced, potentially
resectable hepatocellular carcinoma (HCC). Am Soc Clin Oncol. 38
(15 Suppl):e165932020. View Article : Google Scholar
|
|
4
|
Reig M, Forner A, Rimola J, Ferrer-Fàbrega
J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V,
Salem R, et al: BCLC strategy for prognosis prediction and
treatment recommendation: The 2022 update. J Hepatol. 76:681–693.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ahn JC, Qureshi TA, Singal AG, Li D and
Yang JD: Deep learning in hepatocellular carcinoma: Current status
and future perspectives. World J Hepatol. 13:2039–2051. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kloeckner R, Galle PR and Bruix J: Local
and regional therapies for hepatocellular carcinoma. Hepatology. 73
(Suppl 1):S137–S149. 2021. View Article : Google Scholar
|
|
7
|
Holzner ML, Tabrizian P, Parvin-Nejad FP,
Fei K, Gunasekaran G, Rocha C, Facciuto ME, Florman S and Schwartz
ME: Resection of mixed hepatocellular-cholangiocarcinoma,
hepatocellular carcinoma, and intrahepatic cholangiocarcinoma.
Liver Transpl. 26:888–898. 2020. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Llovet JM, Kelley RK, Villanueva A, Singal
AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and
Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vogel A, Meyer T, Sapisochin G, Salem R
and Saborowski A: Hepatocellular carcinoma. Lancet. 400:1345–1362.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yamada R, Sato M, Kawabata M, Nakatsuka H,
Nakamura K and Takashima S: Hepatic artery embolization in 120
patients with unresectable hepatoma. Radiology. 148:397–401. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Raoul JL, Forner A, Bolondi L, Cheung TT,
Kloeckner R and de Baere T: Updated use of TACE for hepatocellular
carcinoma treatment: How and when to use it based on clinical
evidence. Cancer Treat Rev. 72:28–36. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Department of Medical Administration,
National Health Commission of the People's Republic of China, .
Guideline for diagnosis and treatment of primary liver cancer (2024
edition). Chin J Dig Surg. 23:429–478. 2024.(In Chinese).
|
|
13
|
Llovet JM, Villanueva A, Marrero JA,
Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M,
Mandrekar SJ, et al: Trial design and endpoints in hepatocellular
carcinoma: AASLD consensus conference. Hepatology. 73 (Suppl
1):S158–S191. 2021. View Article : Google Scholar
|
|
14
|
Okusaka T, Okada S, Ueno H, Ikeda M,
Yoshimori M, Shimada K, Yamamoto J, Kosuge T, Yamasaki S, Iwata R,
et al: Evaluation of the therapeutic effect of transcatheter
arterial embolization for hepatocellular carcinoma. Oncology.
58:293–299. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu TZ, Zhang W, Liu QX, Li WH, Ma JQ,
Zhang ZH, Yang MJ, Wang JH, Chen B, Zeng SC, et al: Endovascular
brachytherapy combined with portal vein stenting and transarterial
chemoembolization improves overall survival of hepatocellular
carcinoma patients with main portal vein tumor thrombus.
Oncotarget. 8:12108–12119. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu J, Guo JH, Ji JS, Li YL, Lv WF, Zhu HD,
Sun JH, Ren WX, Zhang FJ, Wang WD, et al: Irradiation stent with
125 I plus TACE versus sorafenib plus TACE for hepatocellular
carcinoma with major portal vein tumor thrombosis: A multicenter
randomized trial. Int J Surg. 109:1188–1198. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang L, Hu B, Li W, Huang P, Zhang S,
Zhong BY and Ni CF: 125I irradiation stent for hepatocellular
carcinoma with main portal vein tumor thrombosis: A systematic
review. Cardiovasc Intervent Radiol. 43:196–203. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fan Z, Qian Z and Hao X: Combination use
of TACE and 125I seed implantation for primary hepatic cancer
complicated by portal vein tumor thrombus: A meta-analysis. J
Interv Radiol. 28:268–275. 2019.
|
|
19
|
Chen L, Sun T, Kan X, Chen S, Ren Y, Cao
Y, Yan L, Liang B, Xiong B and Zheng C: Transarterial
chemoembolization combined with iodine-125 seed implantation for
patients with hepatocellular carcinoma: A retrospective controlled
study. J Int Med Res. 48:3000605209443092020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao F, Gu YK, Huang JH, Zhang FJ and Wu
PH: Clinical value of CT-guided (125)I brachytherapy for
retroperitoneal metastatic lymph node from PHC. Zhonghua Yi Xue Za
Zhi. 93:2155–2157. 2013.(In Chinese). PubMed/NCBI
|
|
21
|
Wang M, Ye X, Yuan G and He S: Advances in
transcatheter arterial chemoembolization for primary liver cancer.
Chin J Exp Surg. 37:1563–1568. 2020.
|
|
22
|
Li B, Gu TS, Zhang YB, Ai N, Liu H and
Zhou ZG: Clinical effect of TACE and three-dimensional conformal
radiotherapy in the treatment of advanced liver cancer. Chin Gen
Pract. 20:4121–4124,4129. 2017.
|
|
23
|
Yoon SM, Ryoo BY, Lee SJ, Kim JH, Shin JH,
An JH, Lee HC and Lim YS: Efficacy and safety of transarterial
chemoembolization plus external beam radiotherapy vs sorafenib in
hepatocellular carcinoma with macroscopic vascular invasion: A
randomized clinical trial. JAMA Oncol. 4:661–669. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li X, Guo W, Guo L, Lau WY, Ge N, Wang K
and Cheng S: Should transarterial chemoembolization be given before
or after intensity-modulated radiotherapy to treat patients with
hepatocellular carcinoma with portal vein tumor thrombus? A
propensity score matching study. Oncotarget. 9:24537–24547. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao Y, Zhu X, Wang H, Dong D, Gao S, Zhu
X and Wang W: Safety and efficacy of transcatheter arterial
chemoembolization plus radiotherapy combined with sorafenib in
hepatocellular carcinoma showing macrovascular invasion. Front
Oncol. 9:10652019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao Q, Zhu K, Yue J, Qi Z, Jiang S, Xu X,
Feng R and Wang R: Comparison of intra-arterial chemoembolization
with and without radiotherapy for advanced hepatocellular carcinoma
with portal vein tumor thrombosis: A meta-analysis. Ther Clin Risk
Manag. 13:21–31. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shui Y, Yu W, Ren X, Guo Y, Xu J, Ma T,
Zhang B, Wu J, Li Q, Hu Q, et al: Stereotactic body radiotherapy
based treatment for hepatocellular carcinoma with extensive portal
vein tumor thrombosis. Radiat Oncol. 13:1882018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu FX, Lu HR, Zhu SL, Li ZH, Zou L, Bai T,
Chen J, Yang TB and Liang SX: Efficacy of three-dimensional
conformal radiotherapy combined with transarterial
chemoembolization for hepatocellular carcinoma with portal vein
tumor thrombus. Onco Targets Ther. 9:7141–7147. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li N, Feng S, Xue J, Wei XB, Shi J, Guo
WX, Lau WY, Wu MC, Cheng SQ and Meng Y: Hepatocellular carcinoma
with main portal vein tumor thrombus: A comparative study comparing
hepatectomy with or without neoadjuvant radiotherapy. HPB (Oxford).
18:549–556. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lewis AR, Padula CA, McKinney JM and
Toskich BB: Ablation plus transarterial embolic therapy for
hepatocellular carcinoma larger than 3 cm: Science, evidence, and
future directions. Semin Intervent Radiol. 36:303–309. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Iezzi R, Pompili M, Posa A, Coppola G,
Gasbarrini A and Bonomo L: Combined locoregional treatment of
patients with hepatocellular carcinoma: State of the art. World J
Gastroenterol. 22:1935–1942. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang YJ, Chen MS, Chen Y, Lau WY and Peng
Z: Long-term outcomes of transcatheter arterial chemoembolization
combined with radiofrequency ablation as an initial treatment for
early-stage hepatocellular carcinoma. JAMA Netw Open.
4:e21269922021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yuan H, Liu F, Li X, Guan Y and Wang M:
Transcatheter arterial chemoembolization combined with simultaneous
DynaCT-guided radiofrequency ablation in the treatment of solitary
large hepatocellular carcinoma. Radiol Med. 124:1–7. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu C, Li T, He JT and Shao H: TACE
combined with microwave ablation therapy vs TACE alone for
treatment of early- and intermediate-stage hepatocellular
carcinomas larger than 5 cm: A meta-analysis. Diagn Interv Radiol.
26:575–583. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang Y, Yu H, Qi L, Liu C, Feng Y, Qi J,
Li J and Zhu Q: Combined radiofrequency ablation or microwave
ablation with transarterial chemoembolization can increase
efficiency in intermediate-stage hepatocellular carcinoma without
more complication: A systematic review and meta-analysis. Int J
Hyperthermia. 39:455–465. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhuang BW, Li W, Xie XH, Hu HT, Lu MD and
Xie XY: Sorafenib versus hepatic arterial infusion chemotherapy for
advanced hepatocellular carcinoma: A systematic review and
meta-analysis. Jpn J Clin Oncol. 49:845–855. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li B, Qiu J, Zheng Y, Shi Y, Zou R, He W,
Yuan Y, Zhang Y, Wang C, Qiu Z, et al: Conversion to resectability
using transarterial chemoembolization combined with hepatic
arterial infusion chemotherapy for initially unresectable
hepatocellular carcinoma. Ann Surg Open. 2:e0572021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huang J, Huang W, Zhan M, Guo Y, Liang L,
Cai M, Lin L, He M, Lian H, Lu L and Zhu K: Drug-eluting bead
transarterial chemoembolization combined with FOLFOX-based hepatic
arterial infusion chemotherapy for large or huge hepatocellular
carcinoma. J Hepatocell Carcinoma. 8:1445–1458. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu BJ, Gao S, Zhu X, Guo JH, Kou FX, Liu
SX, Zhang X, Wang XD, Cao G, Chen H, et al: Combination therapy of
chemoembolization and hepatic arterial infusion chemotherapy in
hepatocellular carcinoma with portal vein tumor thrombosis compared
with chemoembolization alone: A propensity score-matched analysis.
Biomed Res Int. 2021:66703672021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dimri M and Satyanarayana A: Molecular
signaling pathways and therapeutic targets in hepatocellular
carcinoma. Cancers (Basel). 12:4912020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kudo M, Finn RS, Qin S, Han KH, Ikeda K,
Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib
versus sorafenib in first-line treatment of patients with
unresectable hepatocellular carcinoma: A randomised phase 3
non-inferiority trial. Lancet. 391:1163–1173. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kudo M, Ueshima K, Ikeda M, Torimura T,
Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, et al:
Randomised, multicentre prospective trial of transarterial
chemoembolisation (TACE) plus sorafenib as compared with TACE alone
in patients with hepatocellular carcinoma: TACTICS trial. Gut.
69:1492–1501. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Raoul JL, Decaens T, Burak K, Koskinas J,
Villadsen GE, Heurgue-Berlot A, Bayh I, Cheng AL, Kudo M, Lee HC,
et al: 710P-Practice patterns and deterioration of liver function
after transarterial chemoembolization (TACE) in hepatocellular
carcinoma (HCC): Final analysis of OPTIMIS in Europe and Canada.
Ann Oncol. 29 (Suppl 8):viii2402018. View Article : Google Scholar
|
|
44
|
Bruix J, Qin S, Merle P, Granito A, Huang
YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, et al:
Regorafenib for patients with hepatocellular carcinoma who
progressed on sorafenib treatment (RESORCE): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet. 389:56–66.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang H, Xiao W, Han Y, Cao S, Zhang Z,
Chen G, Hu Y and Jin L: Study on safety and efficacy of regorafenib
combined with transcatheter arterial chemoembolization in the
treatment of advanced hepatocellular carcinoma after first-line
targeted therapy. J Gastrointest Oncol. 13:1248–1254. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hatanaka T, Naganuma A and Kakizaki S:
Lenvatinib for hepatocellular carcinoma: A literature review.
Pharmaceuticals (Basel). 14:362021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Koyama N, Saito K, Nishioka Y, Yusa W,
Yamamoto N, Yamada Y, Nokihara H, Koizumi F, Nishio K and Tamura T:
Pharmacodynamic change in plasma angiogenic proteins: A
dose-escalation phase 1 study of the multi-kinase inhibitor
lenvatinib. BMC Cancer. 14:5302014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao
C, Huang F, Tang R, Cheng Y, Huang Z, et al: Lenvatinib combined
with transarterial chemoembolization as first-line treatment for
advanced hepatocellular carcinoma: A phase III, randomized clinical
trial (LAUNCH). J Clin Oncol. 41:117–127. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen S, Wu Z, Shi F, Mai Q, Wang L, Wang
F, Zhuang W, Chen X, Chen H, Xu B, et al: Lenvatinib plus TACE with
or without pembrolizumab for the treatment of initially
unresectable hepatocellular carcinoma harbouring PD-L1 expression:
A retrospective study. J Cancer Res Clin Oncol. 148:2115–2125.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kudo M: A new treatment option for
intermediate-stage hepatocellular carcinoma with high tumor burden:
Initial lenvatinib therapy with subsequent selective TACE. Liver
Cancer. 8:299–311. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kawamura Y, Kobayashi M, Shindoh J,
Kobayashi Y, Okubo S, Tominaga L, Kajiwara A, Kasuya K, Iritani S,
Fujiyama S, et al: Lenvatinib-transarterial chemoembolization
sequential therapy as an effective treatment at progression during
lenvatinib therapy for advanced hepatocellular carcinoma. Liver
Cancer. 9:756–770. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhao S, Zhang T, Dou W, Wang E, Wang M,
Wang C, Du X and Liu L: A comparison of transcatheter arterial
chemoembolization used with and without apatinib for intermediate-
to advanced-stage hepatocellular carcinoma: A systematic review and
meta-analysis. Ann Transl Med. 8:5422020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Liang B, Ma Y, Huang M, Zhang X, Yu L, Luo
Y, Liu R, Zhou S, Xu G, Li HL, et al: 66O TACE combined with
apatinib in patients with intermediate and advanced hepatocellular
carcionma: A prospective, multi-center, randomized clinical trial.
Ann Oncol. 33 (Suppl 9):S14552022. View Article : Google Scholar
|
|
54
|
Ueda S, Hori S, Hori A, Makitani K, Wan K
and Sonomura T: Retrospective study of the efficacy and safety of
chemoembolization with drug-eluting microspheres combined with
intra-arterial infusion of bevacizumab for unresectable
hepatocellular carcinoma. J Hepatocell Carcinoma. 9:973–985. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Fu R, Li Y, Jiang N, Ren BX, Zang CZ, Liu
LJ, Lv WC, Li HM, Weiss S, Li ZY, et al: Inactivation of
endothelial ZEB1 impedes tumor progression and sensitizes tumors to
conventional therapies. J Clin Invest. 130:1252–1270. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Erinjeri JP, Fine GC, Adema GJ, Ahmed M,
Chapiro J, den Brok M, Duran R, Hunt SJ, Johnson DT, Ricke J, et
al: Immunotherapy and the interventional oncologist: Challenges and
opportunities-A society of interventional oncology white paper.
Radiology. 292:25–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Tischfield DJ, Gurevich A, Johnson O,
Gatmaytan I, Nadolski GJ, Soulen MC, Kaplan DE, Furth E, Hunt SJ
and Gade TPF: Transarterial embolization modulates the immune
response within target and nontarget hepatocellular carcinomas in a
rat model. Radiology. 303:215–225. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
No authors listed. IMMUTACE: A phase 2
single-arm, open-label study of transarterial chemoembolization in
combination with nivolumab performed for intermediate-stage
hepatocellular carcinoma. Gastroenterol Hepatol (N Y). 17 (11 Suppl
6):S16–S17. 2021.
|
|
59
|
Marinelli B, Kim E, D'Alessio A, Cedillo
M, Sinha I, Debnath N, Kudo M, Nishida N, Saeed A, Hildebrand H, et
al: Integrated use of PD-1 inhibition and transarterial
chemoembolization for hepatocellular carcinoma: Evaluation of
safety and efficacy in a retrospective, propensity score-matched
study. J Immunother Cancer. 10:e0042052022. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Greten TF, Mauda-Havakuk M, Heinrich B,
Korangy F and Wood BJ: Combined locoregional-immunotherapy for
liver cancer. J Hepatol. 70:999–1007. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Hao MZ, Lin HL, Chen Q, Ye YB, Chen QZ and
Chen MS: Efficacy of transcatheter arterial chemoembolization
combined with cytokine-induced killer cell therapy on
hepatocellular carcinoma: A comparative study. Chin J Cancer.
29:172–177. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
He G, Zheng C, Huo H and Zhang H, Zhu Z,
Li J and Zhang H: TACE combined with dendritic cells and
cytokine-induced killer cells in the treatment of hepatocellular
carcinoma: A meta-analysis. Int Immunopharmacol. 40:436–442. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Llovet JM, Castet F, Heikenwalder M, Maini
MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX and Finn RS:
Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol.
19:151–172. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Zhu HD, Li HL, Huang MS, Yang WZ, Yin GW,
Zhong BY, Sun JH, Jin ZC, Chen JJ, Ge NJ, et al: Transarterial
chemoembolization with PD-(L)1 inhibitors plus molecular targeted
therapies for hepatocellular carcinoma (CHANCE001). Signal
Transduct Target Ther. 8:582023. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zheng L, Fang S, Wu F, Chen W, Chen M,
Weng Q, Wu X, Song J, Zhao Z and Ji J: Efficacy and safety of TACE
combined with sorafenib plus immune checkpoint inhibitors for the
treatment of intermediate and advanced TACE-refractory
hepatocellular carcinoma: A retrospective study. Front Mol Biosci.
7:6093222020. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Cai M, Huang W, Huang J, Shi W, Guo Y,
Liang L, Zhou J, Lin L, Cao B, Chen Y, et al: Transarterial
chemoembolization combined with lenvatinib plus PD-1 inhibitor for
advanced hepatocellular carcinoma: A retrospective cohort study.
Front Immunol. 13:8483872022. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Tao W, Hung TC and Meng W: Efficacy of
TACE combined with TKI and PD-1 inhibitors in conversion therapy
for patients with unresectable hepatocellular carcinoma. Chin J
Oncol Prev Treat. 13:413–419. 2021.(In Chinese).
|
|
68
|
Li X, Chen J, Wang X, Bai T, Lu S, Wei T,
Tang Z, Huang C, Zhang B, Liu B, et al: Outcomes and prognostic
factors in initially unresectable hepatocellular carcinoma treated
using conversion therapy with lenvatinib and TACE plus PD-1
inhibitors. Front Oncol. 13:11106892023. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Lingyi X, Fang F, Wah LK, Yin WW and
Longmei L: Treatment of primary liver cancer by spleen-invigorating
and qi-regulating method combined with TACE: A systematic review.
World J Integr Tradit West Med. 14:1497–1504. 2019.
|
|
70
|
Bin L, Yao L, Ying F and Xianbo W: Effect
of fuzheng jiedu xiaoji formula combined with transhepatic arterial
chemoem-bolization on immune function and survival condition of
primary hepatic carcinoma with qi-yin defi-ciency and toxin-stasis
accumulation syndrome. J Tradit Chin Med. 63:1143–1148. 2022.
|
|
71
|
Ma Y, Wang C, Zhang Q, Peng X, Feng Y and
Meng X: The effects of polysaccharides from Auricularia auricula
(Huaier) in adjuvant anti-gastrointestinal cancer therapy: A
systematic review and network meta-analysis. Pharmacol Res.
132:80–89. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Jang JW, Choi JY, Bae SH, Kim CW, Yoon SK,
Cho SH, Yang JM, Ahn BM, Lee CD, Lee YS, et al: Transarterial
chemo-lipiodolization can reactivate hepatitis B virus replication
in patients with hepatocellular carcinoma. J Hepatol. 41:427–435.
2004. View Article : Google Scholar : PubMed/NCBI
|
